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Objectives. We determined the influence of angiotensin
I-converting enzyme (ACE) insertion (I)/deletion (D) polymor-
phism on the extent of myocardial ischemia in patients with acute
myocardial infarction.
Background. The I/D polymorphism, which in part controls
plasma and tissue expression of ACE, has been implicated in
predisposition to myocardial infarction and ventricular remodel-
ing.
Methods. I/D genotyping, predischarge adenosine–thallium-201
perfusion tomography and radionuclide angiography were per-
formed in 113 patients (72 men, 41 women) with a diagnosis of
acute myocardial infarction. A subgroup of 96 patients also
underwent coronary angiography.
Results. Genotypes DD, ID and II were present in 27, 56 and 30
patients, respectively. There was no significant difference in the
baseline characteristics of patients, total creatine kinase, peak
MB fraction, Killip class, mean ejection fraction or the number of
diseased vessels in patients with the DD, ID or II genotype.
However, the size of the total and the reversible perfusion defects
was greater in those with DD than in those with ID or II genotype
(total defect size [mean 6 SD] 33.7 6 22.5%, 29.5 6 19.2% and
22.2 6 16.0%, respectively [p 5 0.022]; reversible defect size
18.0 6 16.0%, 12.1 6 11.6% and 8.2 6 7.8%, respectively [p 5
0.006]). Occlusion of the infarct-related artery was also more
common in patients with DD genotype (odds ratio 3.9, 95%
confidence interval 1.4 to 11.0). Multivariate analysis showed that
the I/D genotype was an independent predictor of perfusion defect
size and patency of the infarct-related artery (p 5 0.001).
Conclusions. DD genotype was associated with a larger isch-
emic defect and occlusion of the infarct-related artery. Patients
with DD genotype, having a larger ischemic defect, are expected to
be at a greater risk for subsequent cardiovascular events.
(J Am Coll Cardiol 1997;29:1468–73)
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Angiotensin I-converting enzyme (ACE), is a dipeptidyl car-
boxypeptidase (EC 3.4.15.1) that converts angiotensin I to
angiotensin II and inactivates bradykinin (1). Whereas angio-
tensin II is a potent mitotic and trophic hormone, bradykinin is
a cardioprotective hormone (2,3). Gene encoding for ACE is
located on chromosome 17q23 and is expressed in many tissues
including the normal myocardium (4–6). Expression of ACE
in the myocardium is further upregulated in response to
injuries such as infarction or pressure overload (7–9). Dynamic
regulation of expression ACE in the heart along with the
diverse biologic activity of ACE denotes an active role for this
enzyme in many cardiovascular diseases such as heart failure,
ventricular remodeling, cardiac hypertrophy and atherosclero-
sis (10–14). In humans, genetic factors such as insertion
(I)/deletion (D) polymorphism in the ACE gene are strong
determinants of plasma and tissue expression of ACE (15–18).
The I or D polymorphism in the ACE gene is due to the
presence or absence, respectively, of a 287-base pair Alu repeat
sequence in intron 16 of the ACE gene (16). The I/D poly-
morphism accounts for approximately half of the variability of
the plasma level of ACE (17,18). It results in three genotypes:
II, ID and DD. Plasma and tissue levels of ACE are two- to
threefold higher in patients with DD than in those with II
genotype, and patients with ID genotype have an intermediate
level (16,18). Given the influence of ACE I/D polymorphism
on plasma and tissue levels of ACE and the important role of
ACE in cardiovascular disease, the DD genotype has been
implicated as a genetic marker that predisposes to a variety of
cardiovascular diseases (19–22). Two recent studies (23,24)
have shown that ACE I/D polymorphism is also involved in
ventricular remodeling after myocardial infarction (MI). Pinto
et al. (23) showed that the DD genotype was associated with
progressive ventricular dilation and augmented neurohumoral
activation in patients with acute MI. Similarly, Ohmichi et al.
(24) showed that the DD genotype was associated with pro-
gressive global left ventricular dysfunction in patients with
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acute MI. Given the role of ACE I/D polymorphism on
expression of ACE gene and upregulation of ACE expression
in the ischemic zone in patients with acute MI (7,9), we
investigated the relation of ACE I/D polymorphism to the
extent of myocardial ischemia, as assessed by adenosine
thallium-201 perfusion tomography, in 113 consecutive pa-
tients with acute MI.
Methods
Study patients. The study group consisted of 133 unrelated
consecutive patients with a diagnosis of acute MI who were
admitted to our coronary care unit between March 9, 1995 and
June 20, 1996. The diagnosis of MI required two or more of the
following: chest pain of .30 min duration, a rise and fall in
creatine kinase-MB levels and characteristic electrocardio-
graphic (ECG) changes (25). The study protocol was approved
by our institutional review board, and all participating patients
signed an informed consent form. Patients with hemodynamic
instability, recurrent angina requiring coronary artery angio-
plasty or bypass surgery, as well as those with a contraindica-
tion to adenosine infusion, were excluded. One blood sample
was lost during deoxyribonucleic acid (DNA) extraction. A
total of 113 patients completed the study. There was no age
limitation for participation in the study. Conventional risk
factors for coronary artery disease such as family history
(history of MI or coronary artery bypass surgery), hyperten-
sion, diabetes mellitus, hypercholesterolemia and smoking
were obtained by reviewing the records and interviewing the
patients.
Adenosine thallium-201 perfusion tomography and radio-
nuclide angiography. All patients underwent predischarge
(mean 5 6 2 days after MI) adenosine thallium-201 perfusion
tomography and radionuclide angiography as reported from
our laboratory (26). In brief, adenosine was infused intrave-
nously up to a maximal dose of 140 mg/kg per min followed by
injection of 3 mCi of thallium-201. Image acquisition started
5 min after completion of the infusion and was repeated 4 h
later. Computer-generated polar maps, validated and reported
from our laboratory, were used to quantify the size of the total,
fixed and reversible left ventricular perfusion defects (26). Left
ventricular ejection fraction was calculated from radionuclide
angiography according to conventional protocol (26).
Coronary angiography. A subgroup of 96 patients under-
went selective coronary angiography an average of 6 6 2 days
before discharge. The decision to perform coronary angiogra-
phy was made by each patient’s cardiologist, who also had
knowledge of the adenosine thallium-201 perfusion tomogra-
phy result. The infarct-related artery was determined on the
basis of 12-lead surface ECGs in conjunction with the angio-
graphic data and adenosine thallium-201 perfusion tomogra-
phy. Patency of the infarct-related artery was assessed as
patent (Thrombolysis in Myocardial Infarction [TIMI] flow
grade I, II, III) or occluded (TIMI flow grade 0) according to
published criteria (25).
DNA extraction and genotyping. Approximately ten milli-
liters of heparinized blood was collected from each subject for
extraction of DNA. The latter was extracted by the salting out
method, as previously described (27). ACE genotyping was
performed by laboratory personnel who had no knowledge of
the clinical data. ACE genotypes were determined by polymer-
ase chain reaction with the use of dimethyl sulfoxide to
enhance amplification of the I allele (20,28). In brief, a set of
primers was designed to encompass the polymorphic region in
intron 16 of the ACE gene (sense primer 59 CTGGAGAC-
CACTCCCATCCTTTCT39 and antisense primer 59GATGT-
GGCCATCACATTCGTCAGAT39). The polymerase chain
reaction contained 100 hg of DNA template, 0.125 mmol/liter
of each primer, 200 mmol/liter of 4 deoxynucleoside triphos-
phate, 1 U of Taq DNA polymerase and 1.5 mmol/liter of
MgCl2 and 5% dimethyl sulfide. DNA was amplified for 30
cycles, each cycle comprising denaturation at 94°C for 1 min,
annealing at 58°C for 1 min, extension at 72°C for 1 min with
a final extension time of 3 min. The polymerase chain reaction
products were separated by electrophoresis on 2% agarose gel
and identified by ethidium bromide staining.
Statistical analysis. One-way analysis of variance was per-
formed to compare the differences among the variables
grouped according to ACE genotype. If a difference was
detected, the influence of ACE genotype was then analyzed in
autosomal dominant (DD or ID 5 1, II 5 0), codominant
(DD 5 1, ID 5 0.5, II 5 0) and recessive (DD 5 1, ID and II 5
0) modes. Univariate and multivariate logistic regression anal-
yses were performed to determine the percent of explained
variance accounted for by ACE genotypes. Statistical analysis
was accomplished by using MINITAB for Windows, version
10.0 (State College, Pennsylvania). A two-tailed p value , 0.05
was considered significant.
Results
Study patients. The baseline characteristics of the patients
are shown in Table 1. There were no significant differences in
the baseline characteristics of those who completed (113
patients) or did not complete (20 patients) the study (data not
shown).
ACE genotypes and their influence on clinical, scinti-
graphic and angiographic variables. Gel electrophoresis of
amplified polymerase chain reaction products showed 490 bp
Abbreviations and Acronyms
ACE 5 angiotensin I-converting enzyme
CAD 5 coronary artery disease
D 5 deletion
DNA 5 deoxyribonucleic acid
ECG 5 electrocardiogram, electrocardiographic
I 5 insertion
MI 5 myocardial infarction
OR 5 odds ratio
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and 190 bp products, corresponding to the polymerase chain
reaction amplification of I and D alleles, respectively. Individ-
ual patients homozygous for allele D or I were identified by the
presence of 190 bp and 490 bp products on gel electrophoresis,
respectively. Heterozygous patients were identified by the
presence of both 490 bp and 190 bp products.
The II, ID or DD genotype was present in 30 (26%), 56
(50%) and 27 (24%) patients, respectively. The association of
ACE genotypes with clinical variables including thallium-201
perfusion tomography and angiographic variables is shown in
Table 2. Both the total (reversible and fixed) as well as the
reversible (ischemia) perfusion defect sizes were greater in
patients with DD than in those with ID or II genotype, and this
influence was exerted in an autosomal dominant fashion
(Table 2). The infarct-related artery was patent in 84% of
patients with II and in only 55% of patients with DD genotype
(odds ratio [OR] 3.9, 95% confidence interval [CI] 1.4 to 11.0).
The influence of age, gender, heart rate, blood pressure,
previous MI, conventional risk factors for coronary artery
disease (CAD), therapy with thrombolytic agents as well as
ACE genotype on thallium-201 perfusion tomographic indexes
was determined in univariate regression analysis. Only ACE
genotype and therapy with thrombolytic agents were predictors
of the reversible thallium-201 perfusion defect size, accounting
for 6.9% (F 5 9.34, p 5 0.003) and 4.0% (F 5 5.71, p 5 0.019)
of the variability of reversible perfusion defect size, respec-
tively. Predischarge infarct-related artery patency had no sig-
nificant influence on the extent of reversible thallium-201
perfusion defect size (p 5 0.23). In the subgroup of 73 patients
who had a patent predischarge infarct-related artery, ACE
genotype also predicted the reversible thallium-201 perfusion
defect size. The reversible defect size was twice as great in
patients with DD (19.5 6 14.6) as in those with an II (9.1 6
8.1) genotype, and patients with an ID (12.6 6 11.9) genotype
had an intermediate defect size (p 5 0.048). By multivariate
analysis only ACE genotypes (p 5 0.005) and use of thrombo-
lytic agents (p 5 0.035) remained predictors of reversible
thallium-201 perfusion defect size, accounting for 9.8% of its
variability (F 5 7.09, p 5 0.001).
Gender-dependent analysis showed that ACE genotype had
a significant influence on thallium-201 perfusion defect size in
men (Fig. 1) but not in women. The total defect size was 25.7 6
16.8, 29.4 6 20 and 32.1 6 25.9 in women with the II, ID or DD
genotype, respectively (p 5 0.78). However, both the total and
reversible defect sizes were greater in men with ACE genotype
DD than in those with ID or II genotype. Total perfusion
defect size was 19.9 6 15.5% in men with II, 29.5 6 19.2% in
those with ID and 34.3 6 21.2% in those with DD genotype
(p 5 0.017 for autosomal dominant effect). Similarly, the size
of the reversible (ischemic) perfusion defect was 6.1 6 5.5% in
men with II, 9.8 6 9.6% in those with ID and 19.0 6 16.5% in
those with DD genotype (p 5 0.002 for dominant effect). ACE
genotype accounted for 14.3% of the variability of the revers-
ible perfusion defect size in men with acute MI (F 5 12.8, p 5
0.001).
Discussion
We determined the influence of ACE I/D polymorphism on
tomographic thallium-201 perfusion defect size in patients with
acute MI. Our results indicate that ACE genotype DD was
associated with more extensive hypoperfusion and greater
Table 1. Characteristics of Study Patients
Total no. 113 (100%)
Male 72 (64%)
Female 41 (36%)
Age (yr) 54.2 6 9.6
Heart rate (beats/min) 74 6 15
Blood pressure (mm Hg)
Systolic 127 6 20
Diastolic 73 6 12
Prior MI 26 (23%)
Risk factors for CAD
Family history 35 (31%)
Hypercholesterolemia 35 (31%)
Hypertension 61 (54%)
Diabetes mellitus 34 (30%)
Smoking 71 (63%)
Total cholesterol 208.65 6 34.1
LDL 151.4 6 120
HDL 46.1 6 15.7
Triglycerides 173.5 6 85.6
Location of MI
Anterior 51 (45%)
Inferior 29 (26%)
Lateral 30 (27%)
Posterior 3 (2%)
Thrombolytic therapy 36 (32%)
Killip class on admission
I 83
II 24
III 4
IV 2
CK
Total 2,337 6 2,716
Peak MB fraction 156.2 6 233.2
LVEF 46.2 6 12.6
Perfusion defect size (% LV)
Total 28.5 6 19.5%
Reversible 12.5 6 12.4%
Fixed 16.1 6 14.7%
Vessels with CAD (96 pts)
1 45
2 26
$3 25
Infarct-related artery
LAD 46
LCx 27
RCA 21
Not known 2
Data are presented as number (%) of patients or mean value 6 SD. CAD 5
coronary artery disease; CK 5 creatine kinase; HDL 5 high density lipoprotein;
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary
artery; LDL 5 low density lipoprotein; LV 5 left ventricle; LVEF 5 left
ventricular ejection fraction; MI 5 myocardial infarction; pts 5 patients; RCA 5
right coronary artery.
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extent of myocardial ischemia as evidenced by a larger revers-
ible thallium-201 perfusion defect size. This association was
only present in men and accounted for 14.3% of the variability
of reversible perfusion defect size. Concordantly, ACE geno-
type was also associated with patency of the infarct-related
artery and those with DD genotype had a greater likelihood of
having an occluded infarct-related artery (OR 3.9, 95% confi-
dence interval 1.4 to 11.0). ACE genotype was an independent
predictor of thallium-201 perfusion defect size as well as of
infarct-related artery patency. This is the first study to show an
association between ACE I/D polymorphism and extent of
myocardial ischemia in patients with acute MI. There was no
association between this polymorphism and the extent of MI as
measured by creatine kinase-MB levels or fixed thallium-201
perfusion defect.
ACE and myocardial ischemia. The association of ACE
genotype and the extent of myocardial ischemia, defined as
reversible thallium-201 perfusion defect, in patients with MI, is
intriguing. ACE is expressed in the myocardium, which is
partly regulated by ACE I/D polymorphism (6,18). In addition,
its expression in the myocardium is upregulated in the pres-
ence of ischemia and, in particular, in the viable tissue
surrounding the infarct zone (7,9). Given the influence of ACE
genotypes on expression of ACE in the heart, and the role of
ACE in vascular homeostasis, it is not surprising that ACE
genotypes are predictors of myocardial ischemia in patients
with acute MI. The recent demonstration (23,24) of the impact
of ACE genotypes on ventricular remodeling and dysfunction
after MI lends further credit to our results. However, the
molecular mechanism by which ACE genotypes influence
myocardial ischemia has not been explored. The significance of
ACE in myocardial ischemia is emphasized by the observation
that treatment with ACE inhibitors reduces the incidence of
unstable angina and infarction (29,30).
ACE and infarct-related artery patency. Another intrigu-
ing aspect of our results is the association of ACE I/D
polymorphism with infarct-related artery patency. This study is
the first to report such an association and additional studies are
needed to confirm this association. However, given the abun-
dance of data suggesting a role for ACE in thrombosis and
Table 2. Clinical Variables According to Angiotensin-Converting Enzyme Genotype
ACE Genotype
p Value
II
(n 5 30)
ID
(n 5 56)
DD
(n 5 27)
Male/female 18/12 34/22 20/7 0.44
Age (yr) 52.5 6 9.6 54.9 6 8.7 54.8 6 11.4 0.51
Killip class 1.1 6 0.4 1.4 6 0.7 1.4 6 0.7 0.12
CK
Peak
All patients 2,252 6 2,087 2,431 6 3,172 2,214 6 2,221 0.93
Thromb Rx (37 pts) 3,216 6 2,171 4,481 6 4,702 4,413 6 3,282 0.68
No Thromb Rx (76 pts) 1,495 6 1,737 1,433 6 1,237 1,519 6 1,209 0.97
Peak MB fraction
All patients 180.6 6 286.1 159.5 6 246.5 124.6 6 123.7 0.69
Thromb Rx 292.1 6 400.5 285.6 6 349.5 224.5 6 189.8 0.92
No Thromb Rx 92.9 6 94.4 98.1 6 147.1 93.0 6 77.6 0.99
LVEF 47.4 6 13.2 44.0 6 12.9 49.4 6 10.7 0.15
No. of diseased vessels (96 pts) 1.6 6 1.0 1.8 6 1.0 1.9 6 0.9 0.59
IRA patent (73/96) 21/25 (84%) 40/49 (82%) 12/22 (55%) 0.026*
IRA-LAD (46/94)† 14/25 (56%) 24/40 (60%) 8/21 (38%) 0.64
Adenosine thallium-201 defect size
All patients
Total defect 22.2 6 16.0 29.5 6 19.2 33.7 6 22.5 0.022‡
Reversible defect 8.2 6 7.8 12.1 6 11.6 18.0 6 16.0 0.006‡
Fixed defect 14.0 6 13.0 17.3 6 15.8 15.7 6 14.0 0.60
No ACE inhibitor therapy (91 pts)
Total defect 20.7 6 15.7 26.4 6 19.5 32.2 6 21.4 0.048‡
Reversible defect 7.8 6 7.9 10.6 6 11.3 16.4 6 14.2 0.023‡
Fixed defect 12.9 6 12.3 15.8 6 17.1 15.7 6 14.3 0.71
Patients with patent IRA (73 pts)
Total defect 26.2 6 16.4 32.4 6 18.9 34.5 6 22.6 0.14
Reversible defect 9.1 6 8.1 12.6 6 11.9 19.5 6 14.6 0.048‡
Fixed defect 17.1 6 13.9 19.5 6 16.7 16.4 6 15.5 0.78
*Chi-square 7.3, degrees of freedom 2 (DD vs. ID 1 II, p 5 0.011, odds ratio 3.9, 95% confidence interval 1.4 to 11.0). †Infarct-related artery (IRA) could not
be determined in two patients. ‡Autosomal dominant effect. Data presented are number (%) of patients or mean value 6 SD. ACE 5 angiotensin I-converting enzyme;
D 5 deletion; I 5 insertion; Thromb Rx 5 thrombolytic therapy; other abbreviations as in Table 1.
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fibrinolysis, the association between ACE I/D polymorphism
and infarct-related artery patency merits consideration (30).
ACE, through angiotensin II, has been shown (31) to induce
production and secretion of plasminogen activator inhibitor-1,
an important inhibitor of tissue-type plasminogen activator, in
endothelial cells. ACE could also enhance platelet aggrega-
tion, as ACE inhibitors have been shown to reduce platelet
aggregation in humans (32,33). Thus, the ACE genotype DD,
through its influence on higher tissue and plasma levels of
ACE, could promote thrombosis and suppress endogenous
fibrinolytic function. The association of ACE genotypes with
myocardial ischemia and patency of the infarct-related artery
may in part account for the role of ACE genotypes in
ventricular remodeling in patients with MI (23).
ACE genotype and gender. The gender-dependent associ-
ation of ACE genotype with myocardial ischemia is also
intriguing, although the small number of women in this study
prohibits a meaningful interpretation of data related to female
patients. A gender-dependent influence of ACE genotype has
been observed (20,34,35) in patients with MI and left ventric-
ular hypertrophy. It is intriguing that gender-dependent differ-
ences in fertility and blood pressure in mice with deletion of
the ACE gene also have been observed (36). The reason (or
reasons) for gender-dependency of the influence of ACE I/D
polymorphism in predisposing to cardiovascular disease have
not been investigated. The influence of ACE I/D polymor-
phism on plasma and tissue levels of ACE in the context of
gender remains unexplored (16).
Study limitations. Association studies are prone to spuri-
ous results and do not establish causality. In interpreting the
data of an association study, it is necessary to consider several
factors, such as consistency of the results among different
studies, the presence of a biologic gradient (ischemic size . in
DD . in ID . in II genotypes), plausibility of the association
and coherence with the biology of the disease (ACE and
biology of the vessel wall), confirmation by experimentation
(reduction of ischemic events after therapy with ACE inhibi-
tors) and the strength of the association. Our study meets
several of these criteria. However, it is still important to
confirm the observed association of ACE genotypes with the
extent of myocardial ischemia and patency of the infarct-
related artery in additional data sets, in particular in large
populations. Furthermore, long-term follow-up studies are
needed to establish the significance of this observation, and it
remains to be determined whether genotype-based therapy will
influence the outcome of patients with acute MI.
Summary. In summary, we have shown that ACE DD
genotype is associated with more extensive myocardial isch-
emia and more frequent occlusion of the infarct-related artery
in patients with acute MI. These findings may make possible
identification and perhaps early treatment of those who are
likely to develop subsequent cardiovascular events. It is known
(26) that larger ischemic defects predict poor clinical outcome
in patients with MI.
We acknowledge the secretarial assistance of Anna Zamora in preparation of
this manuscript.
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